COVID-19 future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 57: | Line 57: | ||
* Stimulates B and T cells responses | * Stimulates B and T cells responses | ||
| | | | ||
* Requires efficient intradermal gene gun delivery to antigen-presenting cells | |||
* Weaker immune response compared to live vaccine | |||
|- | |- | ||
|Viral Vector | |Viral Vector | ||
| Line 69: | Line 71: | ||
* Competent immune response | * Competent immune response | ||
| | | | ||
* Varied immune response based of mode of delivery | |||
* Th2 bias | |||
|- | |- | ||
|Conjugated subunit | |Conjugated subunit | ||
| Line 84: | Line 88: | ||
* Ease of production | * Ease of production | ||
| | | | ||
* Reduced cost-effectiveness may hinder production | |||
* Adjuvants required | |||
|- | |- | ||
|Virion | |Virion | ||
| Line 98: | Line 104: | ||
* Preservation of whole virus | * Preservation of whole virus | ||
| | | | ||
* Requires optimum nucleocapsid assembly | |||
|- | |- | ||
|Inactivated | |Inactivated | ||
| Line 110: | Line 117: | ||
* Enhanced Protection while ameliorating lung eosinophilic immunopathology | * Enhanced Protection while ameliorating lung eosinophilic immunopathology | ||
| | | | ||
* Hypersensitivity reaction | |||
* Th2-bias | |||
|- | |- | ||
|Live attenuated | |Live attenuated | ||
Revision as of 15:33, 18 March 2020
|
COVID-19 Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
COVID-19 future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of COVID-19 future or investigational therapies |
|
Risk calculators and risk factors for COVID-19 future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Future or Investigational Therapies
Immune Targets
- The B cell and T cell epitopes derived from the spike (S) and nucleocapsid (N) proteins are currently under investigation as immune targets for development of vaccine.
- Phylogenetic similarity between SARS-CoV and COVID-19 at the level of structural proteins S, E, M, and N is providing guidance for development of a possible vaccine.
Current Clinical Trials
The following countries are currently working on the development of a vaccine for COVID-19 (SARS-CoV2)
USA
- Beth Israel Deaconess Medical Center (BIDMC), Boston and Johnson & Johnson (J&J) are currently collaborating to advance COVID-19 vaccine. A Phase I trial is expected to launch during the last quarter of 2020. AdVac and PER.C6 technologies are being used for rapid production.
- National Institute for Allergy and Infectious Diseases (NIAID) has announced that a phase 1 trial has begun for COVID-19 immunization in Washington state.
- The trial includes 45 young, healthy volunteers with different doses of immunization shots co-developed by NIH and Moderna Inc.
Israel
- Researchers at Israel’s Institute for Biological Research are expected to announce in the coming days that they have completed development of a vaccine for COVID-19
China
- China was the first country to release the genetic sequence of the virus on open scientific databases so that research institutes and commercial companies could try to develop treatments and vaccines without needing to obtain samples.
- China has announced the first animal tests.
Australia
- Following successful in vitro experiments, animal testing has begun in University of Queensland in Australia
Prior Work
The following table depicts major vaccine products that have been developed against SARS-CoV and MERS-CoV:
| Vaccine Base | Antigen | Clinical Testing | Pros | Cons |
|---|---|---|---|---|
| DNA |
|
Phase I, II
(NCT03721718) |
|
|
| Viral Vector |
|
Phase I
(NCT03399578, NCT03615911) |
|
|
| Conjugated subunit |
|
|
| |
| Virion |
|
|
| |
| Inactivated |
|
|
| |
| Live attenuated |
|
|